Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy

By Hajioff D.   Enever Y.   Quiney R.   Zuckerman J.   Mackermot K.   Mehta A.  

Journal of Inherited Metabolic Disease, Vol. 26, Iss. 8, 2003-01 ,pp. : 787-794

Springer Publishing Company

Access to resources Recommend Favorite

Enzyme replacement therapy in Fabry disease

By Brady R.   Murray G.   Moore D.   Schiffmann R.  

Journal of Inherited Metabolic Disease, Vol. 24, Iss. 2, 2001-04 ,pp. : 18-24

Springer Publishing Company

Access to resources Recommend Favorite

Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease

By Dehout F.   Roland D.   de Granseigne S.   Guillaume B.   Van Maldergem L.  

Journal of Inherited Metabolic Disease, Vol. 27, Iss. 4, 2004-07 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide

By Whitfield P.   Calvin J.   Hogg S.   O’Driscoll E.   Halsall D.   Burling K.   Maguire G.   Wright N.   Cox T.   Meikle P.   Deegan P.  

Journal of Inherited Metabolic Disease, Vol. 28, Iss. 1, 2005-01 ,pp. : 21-33

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease

By Mills Kevin   Vellodi Ashok   Morris Peter   Cooper Donald   Morris Michael   Young Elisabeth   Winchester Bryan  

European Journal of Pediatrics, Vol. 163, Iss. 10, 2004-10 ,pp. : 595-603

Springer Publishing Company

Access to resources Recommend Favorite